title: Increasing vaginal progesterone gel supplementation after frozen-thawed embryo transfer significantly increases the delivery rate.
abstract: The aim of this study was to evaluate the reproductive outcome in patients receiving frozen-thawed embryo transfer before and after doubling of the vaginal progesterone gel supplementation. The study was a retrospective study performed in The Fertility Clinic, Skive Regional Hospital, Denmark. A total of 346 infertility patients with oligoamenorrhoea undergoing frozen-thawed embryo transfer after priming with oestradiol and vaginal progesterone gel were included. The vaginal progesterone dose was changed from 90 mg (Crinone) once a day to twice a day and the reproductive outcome during the two periods was compared. The pregnancy rate increased significantly after doubling of the progesterone dose (26.7% (90 mg) versus 38.4% (180 mg); P=0.021). Moreover, the early pregnancy loss rate decreased significantly (67.4% versus 43.7%, respectively; P=0.014), which significantly increased the delivery rate (8.7% versus 20.5%, respectively; P=0.002). Doubling of the vaginal progesterone gel supplementation during frozen-thawed embryo transfer cycles decreased the early pregnancy loss rate, resulting in a significantly higher delivery rate. This study evaluated the reproductive outcome of 346 women with oligoamenorrhoea (cycle length >34 days) or amenorrhoea undergoing oestradiol and progesterone priming prior to frozen-thawed embryo transfer. Patients treated with vaginal progesterone gel (Crinone 90 mg) twice daily had a lower risk of pregnancy loss (43.7%) compared with women treated once a day (67.4%). This resulted in a significantly higher delivery rate (20.5% versus 8.7%, respectively).
authors.affiliation: The Fertility Clinic, Skive Regional Hospital, Skive, Denmark. alsbjerg@dadlnet.dk
authors.forename: Birgit
authors.initials: B
authors.lastname: Alsbjerg
authors.forename: Nikolaos P
authors.initials: NP
authors.lastname: Polyzos
authors.forename: Helle Olesen
authors.initials: HO
authors.lastname: Elbaek
authors.forename: Betina Boel
authors.initials: BB
authors.lastname: Povlsen
authors.forename: Claus Yding
authors.initials: CY
authors.lastname: Andersen
authors.forename: Peter
authors.initials: P
authors.lastname: Humaidan
mesh_terms: D000328:Adult; D015925:Cryopreservation; D004305:Dose-Response Relationship, Drug; D004624:Embryo Transfer / Q000379:methods*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007247:Infertility, Female / Q000628:therapy; D011247:Pregnancy; D011256:Pregnancy Outcome; D011374:Progesterone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D012189:Retrospective Studies; D014622:Vaginal Creams, Foams, and Jellies
chemical_list: C400424:Crinone; D014622:Vaginal Creams, Foams, and Jellies; D011374:Progesterone